biostudies-literatureAlbain KSNCI NIH HHSNational Cancer Institute, Department of Health and Human ServicesSouthwest Oncology Group2055-2063https://www.ebi.ac.uk/biostudies/studies/S-EPMC3140679biostudies-literatureUnknown374(9707)<h4>Background</h4>Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy.<h4>Methods</h4>We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concuLancet (London, England)Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.PMC3140679CA63844U10 CA035176U10 CA035178CA58415U10 CA032102CA58416CA58658CA38926CA45461CA35090U10 CA076447CA04919CA45466U10 CA045377N01 CA045807N01 CA035431CA58882CA13612CA12644CA14028CA03096U10 CA058686N01 CA046441CA45450CA25224(SWOG)-8814, INT-0100CA35261U10 CA046113CA76132N01 CA063844U10 CA035431CA35431CA67663U10 CA046282U10 CA022433CA28862U10 CA067663CA42777U10 CA046441CA76462U10 CA037981CA37981CA35200U10 CA042777U10 CA016385CA32734U10 CA035281U10 CA077202CA46282U10 CA045807CA46441CA16385CA35283CA35281CA60138CA12213CA77202-06CA32102N01 CA035119CA35176CA35178U10 CA063844N01 CA027057N01 CA045560U10 CA020319CA52757CA46113CA76447U10 CA058416U10 CA045450U10 CA014028CA58686CA45807U10 CA013612U10 CA012644CA58723U10 CA032102-31U10 CA021115U10 CA004919U10 CA035261U10 CA058882CA22433CA52623CA45377U10 CA027057U10 CA045461CA35996CA35117N01 CA032102CA27057U10 CA035192CA35119U10 CA025224CA76429CA45560CA52654CA46136U10 CA052654CA52650U10 CA035119CA52772U10 CA046368N01 CA004919CA21115CA02599N01 CA035178CA35192N01 CA035176N01 CA013612CA58861CA35128U10 CA035128CA58348U10 CA058348U10 CA058861U10 CA035090CA46368CA35084CA04920CA20319U10 CA045560Ravdin PMGreen SJLichter ASMuss HBOsborne CKBreast Cancer Intergroup of North AmericaHenderson ICBurton GVPritchard KILevine EGIngle JNBarlow WEAbeloff MDAlbain KSSchneider DJLew DMartino SFarrar WBLivingston RBCobau CDKetchel SJfalseAdjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.<h4>Background</h4>Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy.<h4>Methods</h4>We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concu2009-01-01T00:00:00Z2009 Dec2025-04-04T19:31:18.512Z2019-03-27T03:07:16ZS-EPMC31406792000496610.1016/s0140-6736(09)61523-310.1016/S0140-6736(09)61523-3